GlassScriptPhysician profile
Michael A Kaylor
NPI 1104878610
$677.15
in general payments reported to CMS, 2019-2025
15 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.22 · 2020: $22.20 · 2021: $82.46 · 2022: $95.59 · 2023: $226 · 2024: $121 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.33 | 2021-2023 | |
| Astellas Pharma US INC | $70.90 | 2023-2024 | Veozah |
| Lilly USA, LLC | $70.72 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $52.27 | 2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $48.41 | 2021-2025 | |
| Stryker Corporation | $24.38 | 2025 | Insignia, Trident |
| Alnylam Pharmaceuticals INC. | $24.25 | 2023 | Amvuttra |
| Supernus Pharmaceuticals, INC. | $23.68 | 2022 | |
| Allergan, INC. | $22.20 | 2020 | |
| Axsome Therapeutics, INC. | $20.50 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $19.99 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $19.58 | 2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.55 | 2025 | Xifaxan |
| Tris Pharma INC | $15.02 | 2023 | Dyanavel Xr |
| Genentech USA, INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.